SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-018071
Filing Date
2024-01-29
Accepted
2024-01-29 16:00:58
Documents
15
Period of Report
2024-01-23
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d661573d8k.htm   iXBRL 8-K 31066
  Complete submission text file 0001193125-24-018071.txt   189173

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA qncx-20240123.xsd EX-101.SCH 3880
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE qncx-20240123_def.xml EX-101.DEF 13696
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE qncx-20240123_lab.xml EX-101.LAB 22682
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE qncx-20240123_pre.xml EX-101.PRE 14664
17 EXTRACTED XBRL INSTANCE DOCUMENT d661573d8k_htm.xml XML 5526
Mailing Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

IRS No.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38890 | Film No.: 24573525
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)